Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on 1 Aminoindan. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN105063161B reveals high-purity R-1-aminoindane production. Offers cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN105063162A reveals dynamic kinetic resolution for high-purity chiral intermediates. Achieve substantial cost reduction and supply chain reliability in pharmaceutical manufacturing processes.
Patent CN105063164A reveals DKR method for S-6-Methoxy-1-Aminoindane. High purity and yield offer supply chain stability and cost efficiency for pharmaceutical intermediates manufacturing globally.
Patent CN105154513A analysis reveals dynamic kinetic resolution for high-purity chiral intermediates. Achieve substantial cost reduction and supply chain reliability.
Patent CN105063163A reveals enzyme-catalyzed DKR for high-purity chiral intermediates. Offers cost reduction and scalable manufacturing for pharmaceutical supply chains.
Patent CN105154514A enables high-purity (S)-5-methyl-1-aminoindane via dynamic kinetic resolution. Offers cost reduction and supply reliability for pharmaceutical intermediate manufacturing.
This novel chiral resolution method offers high purity and significant cost efficiency for global pharmaceutical intermediate manufacturing supply chains today.
Patent CN105061219A enables high-purity S-1-aminoindane via D-mandelic acid resolution. Offers cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN105017035B details a high-purity DKR method for chiral intermediates. Achieves >99% ee with scalable catalysts for reliable pharmaceutical supply chains.
Patent CN116396189A details a novel B(C6F5)3 catalyzed route for high-purity (S)-(+)-1-indanyl isocyanate, offering significant cost reduction and scalable manufacturing for pharmaceutical intermediates.
Novel patent CN119306612A enables high trans-selectivity. Reduces waste and cost for pharmaceutical intermediate manufacturing supply chains.